| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Andrology, Vol 22, Issue 5 793-797, Copyright © 2001 by The American Society of Andrology
JOURNAL ARTICLE |
A. T. Guay, J. B. Perez, J. Jacobson and R. A. Newton
Department of Endocrinology, Lahey Clinic, Peabody, Massachusetts 01960, USA. andre.t.guay@lahey.org
The objective of this study was to determine the efficacy and safety of sildenafil in patients with erectile dysfunction (ED) and associated organic risk factors in a multispecialty clinic. Patients (n = 521) were diagnosed with ED based on self-assessment. Associated risk factors were managed by medication or life-style modifications, or both, before treatment with sildenafil for ED. Patients received a 50-mg dose of sildenafil that could be adjusted to 100 mg or 25 mg based on tolerability and efficacy. Patients recorded the number of successful intercourse encounters for 6 to 8 weeks, and the number of adverse events. Overall, there was an 82% successful intercourse rate with sildenafil treatment. The predominant associated risk factors for ED were hypertension (39%), hypogonadism (37%), and multiple medications (34%). Common adverse events due to sildenafil treatment were mild to moderate in nature and resulted in <2% patient discontinuation. Clinicians should be particularly careful to evaluate patients presenting with ED because the condition can be accompanied by a wide spectrum of risk factors requiring monitoring and treatment. However, with adequate treatment and control of these risk factors, the use of sildenafil in a representative population of men with ED in a multispecialty clinic can achieve a higher efficacy rate than previous studies have indicated.
This article has been cited by other articles:
 |
|
 |
|
  A. L. Burnett Molecular Pharmacotherapeutic Targeting of PDE5 for Preservation of Penile Health J Androl, January 1, 2008; 29(1): 3 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N McMahon, C. J Smith, and R. Shabsigh Treating erectile dysfunction when PDE5 inhibitors fail BMJ, March 11, 2006; 332(7541): 589 - 592. [Full Text] [PDF]
|
|
|
|
|
|
V. Rochira, A. Balestrieri, B. Madeo, A. R. M. Granata, and C. Carani Sildenafil Improves Sleep-Related Erections in Hypogonadal Men: Evidence From a Randomized, Placebo-Controlled, Crossover Study of a Synergic Role for Both Testosterone and Sildenafil on Penile Erections J Androl, March 1, 2006; 27(2): 165 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Sullivan, T. H. Teal, I. P. Luttrell, K. B. Tran, M. A. Peters, and H. Wessells Microarray analysis reveals novel gene expression changes associated with erectile dysfunction in diabetic rats Physiol Genomics, October 17, 2005; 23(2): 192 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Carson Erectile Dysfunction: Evaluation and New Treatment Options Psychosom Med, September 1, 2004; 66(5): 664 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Morelli, S. Filippi, R. Mancina, M. Luconi, L. Vignozzi, M. Marini, C. Orlando, G. B. Vannelli, A. Aversa, A. Natali, et al. Androgens Regulate Phosphodiesterase Type 5 Expression and Functional Activity in Corpora Cavernosa Endocrinology, May 1, 2004; 145(5): 2253 - 2263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Guay Optimizing Response To Phosphodiesterase Therapy: Impact of Risk-Factor Management J Androl, November 1, 2003; 24(6_suppl): S59 - S62. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
